Nanoparticle-Based Treatment Approaches for Skin Cancer: A Systematic Review

Nanoparticles have shown marked promise as both antineoplastic agents and drug carriers. Despite strides made in immunomodulation, low success rates toxicity remain limitations within the clinical oncology setting. In present review, we assess advances delivery nanoparticles, for systemic topical use, skin cancer treatment. A systematic review of controlled trials, meta-analyses, Cochrane articles was conducted. Eligibility criteria included: (1) a primary focus on nanoparticle utility cancer; (2) available metrics prevention treatment outcomes; (3) detailed subject population; (4) English language; (5) archived full-text journal articles. total 43 were selected review. Qualitative analysis revealed that nanoscale systems demonstrate significant anti-metastasis properties: increased bioavailability, reduced toxicity, enhanced permeability retention effect, well tumor growth inhibition, among others. Nanoformulations cancers largely lagged behind those tested other cancers–several which commercialized formulae. However, emerging evidence has indicated powerful role these carriers targeting metastatic cancers.